A compound found in marijuana may be a big benefit to patients who suffer from a rare form of epilepsy.
Known as cannabidiol, or CBD, the cannabis derivative reduced the chance of seizure among patients with Dravet syndrome by nearly 40 percent, according to a new study appearing in the New England Journal of Medicine.
The new study is especially promising because pharmaceutical interventions for the rare — and sometimes fatal — condition were previously lacking.
“Dravet syndrome is a complex childhood epilepsy disorder that is associated with drug-resistant seizures and a high mortality rate,” report the study authors.
While cannabidiol comes from the marijuana plant, the substance “does not contain psychoactive properties that induce a high,” explain